Fred Saad, MD, discusses the findings of ACIS, a phase 3 clinical trial of apalutamide and abiraterone acetate plus prednisone vs abiraterone alone for chemotherapy-naive CRPC.

Felix Feng, MD, talks about identifying molecular determinants of response to apalutamide in nonmetastatic CRPC in the SPARTAN trial.

Todd Cohen, MD, highlights how certain patients with prostate cancer may be able to forgo receipt of combined ADT.

Jonathan Tward, MD, discusses how the link between clinical cell-cycle risk score and post-RT metastasis can identify patients eligible to forgo combined ADT.

Kim Chi, MD, discusses final analysis results from the phase 3 TITAN trial of apalutamide vs placebo for patients with metastatic CSPC receiving ADT.

Dr Sokolova highlights a systematic approach to germline testing in veterans with metastatic prostate cancer.

Dr Sokolova discusses the GENTleMEN study and important differences between somatic and germline testing for patients with prostate cancer.

Daniel Gioeli, PhD, and colleagues have found a potential key to regulating the progression of prostate cancer.